Dr. Eric Winer
Dr. Winer received his MD from Yale University in 1983, and later completed training in internal medicine and served as chief resident at Yale-New Haven Hospital. He subsequently was a fellow in hematology-oncology at Duke University Medical Center, and from 1989 to 1997 served on the Duke faculty, where he became co-director of the multidisciplinary breast program. In 1997, he joined Brigham and Women's Hospital and DFCI, where he is director of the Breast Oncology Center.
Medical Oncology, 1989
Internal Medicine, 1987
Duke University Medical Center, Hematology & Oncology
Yale University School of Medicine, Chief Medical Resident
Yale University School of Medicine, Internal Medicine
Yale University School of Medicine
Gianni Bonadonna Breast Cancer Award and Lecture, American Society of Clinical Oncology, 2017
The William L. McGuire Memorial Lectureship, San Antonio Breast Cancer Symposium, 2016
Advancing the Careers of Women Faculty Award, Dana-Farber Cancer Institute, 2013
A. Clifford Barger Excellence in Mentoring Award, Harvard Medical School, 2009
Tisch Award for Outstanding Achievement, Dana-Farber Cancer Institute, 2006
Claire W. and Richard P. Morse Research Award, 2002
Joseph Sokal Memorial Lecturer, Duke University, 1999
Clinical Research in Breast Cancer
Our group in the Breast Oncology Center (BOC), which includes over 25 physicians and investigators, is dedicated to improving the care of women with breast cancer through the conduct of clinical trials. More than 25 trials - spanning the spectrum of the disease - are currently open to women with breast cancer. Some focus on local treatment and adjuvant systemic therapy, while others explore questions in the preoperative setting. Our group published the first report of a preoperative trial using trastuzumab in women with stage II/III breast cancer. This trial, in turn, led to a series of studies in women with early-stage, HER2-positive disease.
We also test new treatments in women with advanced disease, with the hope that, if effective, they can be used to treat women with early-stage disease to prevent recurrence. Our group is investigating a variety of novel agents that target specific pathways within cancer cells and the surrounding tissue. We incorporate translational research endpoints in the vast majority of our trials to gain a better understanding of molecular factors that may elucidate mechanisms of action and predictors of treatment effect. As a result of our work, we have built a sizeable bank of tumor and serum specimens, which are linked to detailed clinical data for each patient who has received longitudinal care in the program. We plan to expand this effort in the metastatic setting and collect serial biopsies over time to understand the molecular differences between primary and metastatic tumors and the resistance mechanisms that develop over the course of the disease.
Our group is also committed to research that will improve psychosocial functioning of women with early-stage and advanced breast cancer. One recent study seeks to better understand the experience of women newly diagnosed with ductal carcinoma in situ; another examines issues facing breast cancer survivors. A new cohort study in eastern Massachusetts will focus on young women with breast cancer. We believe that the research output of the BOC, which has increased dramatically over the past 8 years, will continue to expand and have a tangible impact on the disease over the next 5 to 10 years.